143 related articles for article (PubMed ID: 34871036)
1. Myeloid Toxicity of Radionuclide Cancer Therapy.
Kesavan M; Turner JH
Cancer Biother Radiopharm; 2022 Apr; 37(3):164-172. PubMed ID: 34871036
[TBL] [Abstract][Full Text] [Related]
2. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES
Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
[TBL] [Abstract][Full Text] [Related]
3. Myelotoxicity of Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Decade of Experience.
Kesavan M; Turner JH
Cancer Biother Radiopharm; 2016 Aug; 31(6):189-98. PubMed ID: 27419665
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in theranostics and challenges for the future.
Turner JH
Br J Radiol; 2018 Nov; 91(1091):20170893. PubMed ID: 29565650
[TBL] [Abstract][Full Text] [Related]
5. [
Hofman MS; Violet J; Hicks RJ; Ferdinandus J; Thang SP; Akhurst T; Iravani A; Kong G; Ravi Kumar A; Murphy DG; Eu P; Jackson P; Scalzo M; Williams SG; Sandhu S
Lancet Oncol; 2018 Jun; 19(6):825-833. PubMed ID: 29752180
[TBL] [Abstract][Full Text] [Related]
6. Salvage Radiopeptide Therapy of Advanced Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen: Efficacy and Safety in Routine Practice.
Kesavan M; Turner JH; Meyrick D; Yeo S; Cardaci G; Lenzo NP
Cancer Biother Radiopharm; 2018 Sep; 33(7):274-281. PubMed ID: 29989440
[TBL] [Abstract][Full Text] [Related]
7. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
[TBL] [Abstract][Full Text] [Related]
8. Neuroendocrine Tumor Theranostics: An Update and Emerging Applications in Clinical Practice.
Sheikhbahaei S; Sadaghiani MS; Rowe SP; Solnes LB
AJR Am J Roentgenol; 2021 Aug; 217(2):495-506. PubMed ID: 34076455
[No Abstract] [Full Text] [Related]
9. Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with
Heck MM; Tauber R; Schwaiger S; Retz M; D'Alessandria C; Maurer T; Gafita A; Wester HJ; Gschwend JE; Weber WA; Schwaiger M; Knorr K; Eiber M
Eur Urol; 2019 Jun; 75(6):920-926. PubMed ID: 30473431
[TBL] [Abstract][Full Text] [Related]
10. A Retrospective Analysis of the Safety and Activity of Lutetium-177-Prostate-Specific Membrane Antigen Radionuclide Treatment in Older Patients with Metastatic Castration-Resistant Prostate Cancer.
Leibowitz R; Davidson T; Gadot M; Aharon M; Malki A; Levartovsky M; Oedegaard C; Saad A; Sandler I; Ben-Haim S; Domachevsky L; Berger R
Oncologist; 2020 Sep; 25(9):787-792. PubMed ID: 32430954
[TBL] [Abstract][Full Text] [Related]
11. The Role of Theranostics in Prostate Cancer.
O'Dwyer E; Bodei L; Morris MJ
Semin Radiat Oncol; 2021 Jan; 31(1):71-82. PubMed ID: 33246638
[TBL] [Abstract][Full Text] [Related]
12. Comparative assessment of docetaxel for safety and efficacy between hormone-sensitive and castration-resistant metastatic prostate cancer.
Mager R; Savko O; Böhm K; Thomas A; Dotzauer R; Borgmann H; Jäger W; Thomas C; Haferkamp A; Höfner T; Tsaur I
Urol Oncol; 2019 Dec; 37(12):999-1005. PubMed ID: 31377168
[TBL] [Abstract][Full Text] [Related]
13. Prognostic and Theranostic Applications of Positron Emission Tomography for a Personalized Approach to Metastatic Castration-Resistant Prostate Cancer.
Filippi L; Frantellizzi V; Chiaravalloti A; Pontico M; De Feo MS; Corica F; Montebello M; Schillaci O; De Vincentis G; Bagni O
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33809749
[TBL] [Abstract][Full Text] [Related]
14. Theranostics of Metastatic Prostate Cancer Applying
Mirzaei S; Mohammed F; Zandieh S
Curr Radiopharm; 2021; 14(4):354-358. PubMed ID: 32900357
[TBL] [Abstract][Full Text] [Related]
15. A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.
Martin GA; Chen AH; Parikh K
Pharmacotherapy; 2017 Nov; 37(11):1406-1414. PubMed ID: 28895177
[TBL] [Abstract][Full Text] [Related]
16. The potential of PSMA-targeted alpha therapy in the management of prostate cancer.
Filippi L; Chiaravalloti A; Schillaci O; Bagni O
Expert Rev Anticancer Ther; 2020 Oct; 20(10):823-829. PubMed ID: 32820953
[TBL] [Abstract][Full Text] [Related]
17. Examining the ability of the Cancer and Aging Research Group tool to predict toxicity in older men receiving chemotherapy or androgen-receptor-targeted therapy for metastatic castration-resistant prostate cancer.
Alibhai SMH; Breunis H; Hansen AR; Gregg R; Warde P; Timilshina N; Tomlinson G; Joshua AM; Hotte S; Fleshner N; Emmenegger U
Cancer; 2021 Jul; 127(14):2587-2594. PubMed ID: 33798267
[TBL] [Abstract][Full Text] [Related]
18. Radioligand Therapy With 177Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer.
Rahbar K; Bode A; Weckesser M; Avramovic N; Claesener M; Stegger L; Bögemann M
Clin Nucl Med; 2016 Jul; 41(7):522-8. PubMed ID: 27088387
[TBL] [Abstract][Full Text] [Related]
19. Metabolism and pharmacokinetics of radium-223 in prostate cancer.
Yeku O; Slovin SF
Expert Opin Drug Metab Toxicol; 2015 May; 11(5):843-9. PubMed ID: 25740232
[TBL] [Abstract][Full Text] [Related]
20. Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment.
Jadvar H
AJR Am J Roentgenol; 2017 Aug; 209(2):277-288. PubMed ID: 28463538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]